SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolchok JD, Motzer RJ. Management of renal cell carcinoma. Oncology (Williston Park) 2000; 14: 2936
  • 2
    McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 13341
  • 3
    Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29 (Suppl. 14): 39
  • 4
    Woodburn J. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 24150
  • 5
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 1723
  • 6
    Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99101
  • 7
    Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005; 104: 232333
  • 8
    Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006; 24 (Suppl): 217s, Abstract 4502
  • 9
    Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002; 99: 537
  • 10
    Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121: 17993
  • 11
    Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 90918
  • 12
    Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24: 930s (LBA4)
  • 13
    Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006; 24: 224s, Abstract 4530
  • 14
    Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 135964
  • 15
    Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001; 80: 138
  • 16
    Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 2715
  • 17
    Gnarra JR, Zhou S, Merrill MJ et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 1058994
  • 18
    Kourembanas S, Hannan RL, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene human endothelial cells J Clin Invest 1990; 86: 6704
  • 19
    Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002; 9: 50914
  • 20
    Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 42734
  • 21
    Wilhelm S, Chien DS. BAY 43–9006: preclinical data. Curr Pharm Des 2002; 8: 22557
  • 22
    Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099109
  • 23
    Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43–9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006; 42: 54856
  • 24
    Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43–9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 185561
  • 25
    Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43–9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 168894
  • 26
    Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 96572
  • 27
    Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 250512
  • 28
    Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20: 447884
  • 29
    Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23: 223s, Abstract 4510
  • 30
    Eisen T, Bukowski RM, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. J Clin Oncol 2006; 24: 223s, Abstract 4524
  • 31
    Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24: 217s, Abstract 4501
  • 32
    Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97: 166371
  • 33
    Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 2535
  • 34
    Fiedler W, Serve H, Dohner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 98693
  • 35
    O’Farrell AM, Foran JM, Fiedler W et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 546576
  • 36
    Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1624
  • 37
    Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 251624
  • 38
    De Mulder PH, Roigas J, Gillessen S et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24: 223s, Abstract 4529
  • 39
    Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 930s (LBA3)
  • 40
    Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 547483
  • 41
    Rini B, Rixe O, Bukowski R et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23: 223s, Abstract 4509
  • 42
    Escudier B, Venner P, Buckowski R et al. Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol 2003; 22: 211s, Abstract 844
  • 43
    Drevs J, Muller-Driver R, Wittig C et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002; 62: 401522
  • 44
    Tamaskar P, Shaheen L, Wood L et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol 2006; 24: 240s, Abstract 4597
  • 45
    Rini BI, George DJ, Michaelson MD et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 220s, Abstract 4522
  • 46
    Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon-á2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC). SWOG 0412. J Clin Oncol 2006; 24: 223s, Abstract 4525
  • 47
    Gollob J, Richmond T, Jones J et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-á2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 2006; 24: 226s, Abstract 4538
  • 48
    Sosman JA, Flaherty K, Atkins MB et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 2006; 24: 128s, Abstract 3031
  • 49
    Ronnen EA, Kondagunta GV, Lau C et al. A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24: 225s, Abstract 4537
  • 50
    Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 788996
  • 51
    Bukowski RM, Kabbinavar F, Figlin RA et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol 2006; 24: 222s, Abstract 4523
  • 52
    Shaked Y, Bocci G, Munoz R et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005; 5: 5519